SCHEMBL319629

SCHEMBL319629

CCC(OC)N1CCCCC1

nearest known ligand 0.35

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.33
TSHR P16473 1/20 0.31
ACHE P22303 1/20 0.31
RAB9A P51151 1/20 0.31
MAPT P10636 1/20 0.30
MAPK1 P28482 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3306791 0.98 ALDH1A1 (0.30) ALDH1A1
SCHEMBL10924624 0.87
SCHEMBL3303141 0.82 SLC6A3 (0.37) MAPTMAPK1NPSR1L3MBTL1
SCHEMBL6692856 0.81 FDPS (0.33) ALDH1A1MAPTMAPK1NPSR1L3MBTL1
SCHEMBL3302657 0.79 SLC6A3 (0.38)
SCHEMBL10926783 0.79 THRB (0.32)
SCHEMBL8112088 0.79 DPP7 (0.31)
SCHEMBL10925842 0.79 MC4R (0.37)
SCHEMBL3307512 0.79 HRH3 (0.41) ALDH1A1TSHRMAPTMAPK1NPSR1
SCHEMBL4876026 0.78 THRB (0.35) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2602307-B1 LUBRICANT COMPOSITION WITH RUST INHIBITING PROPERTIES AND WITH AN IONIC LIQUID AS THE BASE OIL KYODO YUSHI (JP) 2017-05-10 EP claimed
EP-3676221-A1 METHOD FOR MANUFACTURING VERTICALLY ALIGNED CARBON NANOTUBES, AND ELECTROCHEMICAL CAPACITORS USING THESE NANOTUBES AS ELECTRODES Nawatechnologies (FR) 2020-07-08 EP disclosed
EP-3666860-A1 ANTI-FLAKING AGENT AND LUBRICANT COMPOSITION COMPRISING THE SAME Kyodo Yushi Co., Ltd. (JP) 2020-06-17 EP disclosed
WO-2019043320-A1 METHOD FOR MANUFACTURING VERTICALLY ALIGNED CARBON NANOTUBES, AND ELECTROCHEMICAL CAPACITORS USING THESE NANOTUBES AS ELECTRODES NAWATECHNOLOGIES (FR) 2019-03-07 WO disclosed
EP-2958181-B1 NON-AQUEOUS ELECTROLYTIC SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEM CORP (JP) 2017-06-14 EP disclosed
US-9653754-B2 Nonaqueous electrolytes and nonaqueous-electrolyte secondary batteries employing the same MITSUBISHI CHEMICAL CORPORATION (JP) 2017-05-16 US disclosed
EP-2602307-B1 LUBRICANT COMPOSITION WITH RUST INHIBITING PROPERTIES AND WITH AN IONIC LIQUID AS THE BASE OIL KYODO YUSHI (JP) 2017-05-10 EP disclosed
US-9620814-B2 2017-04-11 US disclosed
US-9515348-B2 Nonaqueous electrolytic solution and nonaqueous-electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2016-12-06 US disclosed
US-9231277-B2 Nonaqueous electrolytes and nonaqueous-electrolyte secondary batteries employing the same MITSUBISHI CHEMICAL CORPORATION (JP) 2016-01-05 US disclosed
EP-2535976-A1 NONAQUEOUS ELECTROLYTE SOLUTION, AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY Mitsubishi Chemical Corporation (JP) 2012-12-19 EP disclosed
US-20120308881-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQEUOUS-ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2012-12-06 US disclosed
US-20120264010-A1 NONAQUEOUS ELECTROLYTES AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERIES EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2012-10-18 US disclosed
WO-2012004317-A1 METHOD OF PREPARING A COMPOSITE, COMPOSITE THUS OBTAINED AND USES THEREOF Commissariat à l'énergie atomique et aux énergies alternatives (FR) 2012-01-12 WO disclosed
US-7928231-B2 Thienopyrazoles AVENTIS PHARMACEUTICALS INC. (US) 2011-04-19 US disclosed
US-20100099031-A1 NONAQUEOUS ELECTROLYTES AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERIES EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2010-04-22 US disclosed
EP-2166611-A1 NONAQUEOUS ELECTROLYTE, AND RECHARGEABLE BATTERY WITH THE NONAQUEOUS ELECTROLYTE Mitsubishi Chemical Corporation (JP) 2010-03-24 EP disclosed
US-20100056514-A1 THIENOPYRAZOLES AVENTIS PHARMACEUTICALS INC. (US) 2010-03-04 US disclosed
US-7518000-B2 Thienopyrazoles AVENTIS PHARMACEUTICALS, INC. (US) 2009-04-14 US disclosed
US-7312235-B2 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056514-A1 THIENOPYRAZOLES ITK, IL2, TYK2 ALDH1A1 2271/4885TSHR 1269/4885ACHE 4380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.